Conformationally constrained backbone cyclized peptide analogs
AssigneeDeveloGen Israel Ltd.
InventorsChaim Gilon, Doron Eren, Irina Zeltser, Alon Seri-Levy, Gal Bitan, Dan Muller
Life of this patent
Estimating the term…
Loading patent…
AssigneeDeveloGen Israel Ltd.
InventorsChaim Gilon, Doron Eren, Irina Zeltser, Alon Seri-Levy, Gal Bitan, Dan Muller
Estimating the term…
Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are Nα(ω-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these Nα(ω-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is specifically exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.
A backbone cyclized peptide analog comprising a peptide sequence that incorporates at least two building units, each of which contains one nitrogen atom of the peptide backbone connected to a bridging group comprising a disulfide, amide, thioether, thioester, imine, ether, or alkene bridge, wherein at least two of said building units are joined together to form a cyclic structure.
A method for the preparation of cyclic peptides of the general Formula (I):
A method for the preparation of cyclic peptides of the general Formula (II):
Dependencies are inferred from the claim text.